Researcher
Alfons Verbruggen
- Disciplines:Medicinal products, Biomarker discovery and evaluation, Drug discovery and development, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Faculty of Pharmaceutical Sciences (Faculty)
Member
From1 Oct 2020 → Today - Radiopharmaceutical Research (Division)
Member
From1 Oct 1999 → 30 Sep 2019
Projects
1 - 10 of 10
- translational study of the modulation of fosfodiesterase type 10A expression by dopaminergic neurotransmission using molecular imagingFrom1 Jan 2013 → 31 Dec 2016Funding: FWO research project (including WEAVE projects)
- Oncocidia_the novel anticancer therapy: phase 0 clinical study.From1 Jan 2013 → 31 Dec 2013Funding: IOF - Industrial Research Fund
- Development and evaluation of PET ligands for the in vivo visualisation of phosphodiesterase type 5 (PDE5).From1 Jan 2012 → 31 Dec 2015Funding: FWO research project (including WEAVE projects)
- Synthesis and biological evaluation of carbon-11 and fluorine-18 labelled P2X7-receptor ligands for diagnosis of neurological diseases using positron emission tomographyFrom1 Oct 2011 → 30 Sep 2015Funding: FWO fellowships
- In vivo molecular imaging research (IMIR).From1 Nov 2010 → 31 Oct 2018Funding: BOF - Concerted Research Project from 1994
- Molecular and functional imaging as a pivotal tool for translational medicine in the field of neuroscience and oncology: a platform creating a bridge between basic research, clinical development and industrial application.From1 Oct 2010 → 30 Sep 2014Funding: IOF - Industrial Research Fund
- Preclinical validation and first in man study of PET radioligands for the cannabinoidreceptor type 2.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project (including WEAVE projects)
- Synthesis and (pre)clinical evaluation of PET radioligands for in vivo visualization of phosphodiesterase 10, an enzyme involved in neurological and psychiatric disorders.From1 Oct 2009 → 30 Sep 2010Funding: BOF - Other initiatives
- Development of a radiolabelled probes for the in vivo visualisation of the TRPV1 receptor with PETFrom1 Oct 2008 → 24 Jan 2013Funding: IWT personal funding - strategic basic research grants
- Anti-kanker therapie versterkt door kleine radioactief gelabelde compounds met affiniteit voor necrosis (sRALNAC): een Prrof-of-Principle experiment ter ondersteuning van een nieuw patent aanvraag.From1 Jul 2008 → 30 Jun 2009Funding: IOF - Industrial Research Fund
Publications
21 - 30 of 124
- Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807(2016)
Authors: Lieven Declercq, Sofie Celen, Joan Lecina, Thomas Tousseyn, Rik Vandenberghe, Koen Van Laere, Alfons Verbruggen, Guy Bormans
Pages: 1 - 15 - Quantification of TSPO overexpression in a rat model of local neuroinflammation induced by intracerebral injection of LPS by the use of [(18)F]DPA-714 PET(2016)
Authors: Michel Koole, Sofie Celen, Bart de Laat, Alfons Verbruggen, Koen Van Laere, Guy Bormans, Cindy Casteels
Pages: 163 - 72 - Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT(2016)
Authors: Lieven D Declercq, Rik Vandenberghe, Koen Van Laere, Alfons Verbruggen, Guy Bormans
- PET imaging of neuroinflammation targeting TSPO and P2X7 receptor(2015)
Authors: Dieter Ory, Guy Bormans, Zeger Debyser, Alfons Verbruggen
- Retention of [(18)F]fluoride on reversed phase HPLC columns(2015)
Authors: Dieter Ory, Lieven Declercq, Frederik Cleeren, Koen Van Laere, Alfons Verbruggen, Guy Bormans
Pages: 209 - 14 - PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide(2015)
Authors: Dieter Ory, Tom Dresselaers, Willy Gsell, Sofie Celen, Cindy Casteels, Uwe Himmelreich, Zeger Debyser, Koen Van Laere, Alfons Verbruggen, Guy Bormans
Pages: 753 - 761 - In vitro evaluation of new tau PET tracer candidates using [18F]T808 and [18F]T808 AD brain slice autoradiography binding inhibition studies(2015)
Authors: Lieven Declercq, Sofie Celen, Thomas Tousseyn, Diederik Moechars, Jesus Alcazar, Manuela Ariza, Katleen Fierens, Rik Vandenberghe, Jose Ignacio Andres, Xavier Langlois, et al.
Pages: S236 - S236 - Radiosynthesis and preclinical evaluation of new (AlF)-F-18-labelled Urea-based PSMA inhibitors for PET imaging of prostate cancer(2015)
Authors: Frederik Cleeren, Joan Lecina, Emilie Billaud, Muneer Ahamed, Bryan Holvoet, Karolien Goffin, Christophe Deroose, Alfons Verbruggen, Guy Bormans
Pages: S243 - S243 - Radiopharmaceuticals are special, but is this recognized? The possible impact of the new Clinical Trials Regulation on the preparation of radiopharmaceuticals(2014)
Authors: Alfons Verbruggen
Pages: 2005 - 2007 - Retention of [18F]fluoride on different reversed phase (RP) HPLC columns(2014)
Authors: Guy Bormans, Alfons Verbruggen
Pages: S243 - S244
Patents
1 - 4 of 4